Summary: Aurora Therapeutics, founded by CRISPR pioneers Jennifer Doudna and Fyodor Urnov, has officially launched to transform personalized gene editing into a scalable approach for treating rare genetic diseases. Backed by Menlo Ventures with $16 million in seed funding, Aurora combines modular gene editors, AI-driven guide design, and innovative regulatory strategies to develop therapies that can address multiple mutations in parallel. The company’s first focus is phenylketonuria (PKU), aiming to provide durable, population-scale treatments for patients with rare mutations. Aurora’s leadership team brings extensive experience in rare disease drug development, while its model leverages emerging regulatory frameworks to make personalized therapies economically and operationally viable.